Metabolic diseases and pro- and prebiotics: Mechanistic insights

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Nakamura, Yukiko K ^a   Omaye, Stanley T ^a  

^a UNIVERSITY OF NEVADA   (United States)

Author keywords

Inflammation; Intestinal bacteria; Lipopolysaccharides; Obesity; Prebiotics; Probiotics; Type 2 diabetes

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; EXOPOLYSACCHARIDE; FRUCTOSE OLIGOSACCHARIDE; INULIN; PREBIOTIC AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 4;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; CHRONIC INFLAMMATION; DIETARY INTAKE; DISEASE COURSE; DOSE RESPONSE; ENDOTOXEMIA; FAT INTAKE; HEALTH BEHAVIOR; HUMAN; INFECTION; INFLAMMATION; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS KEFIRANOFACIENS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LIPID DIET; MACRONUTRIENT; MEAT; METABOLIC DISORDER; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVERNUTRITION; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PREVENTIVE MEDICINE; REVIEW; SUGAR INTAKE;

BACTERIA (MICROORGANISMS);

EID: 84862277039     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-60     Document Type: Review

References (98)

1. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Gross LS, Li L, Ford ES, Liu S, Am J Clin Nutr 2004 79 774 779 15113714 (Pubitemid 41103877)
2. Obesity, inflammation, and insulin resistance. Shoelson SE, Herrero L, Naaz A, Gastroenterology 2007 132 2169 2180 10.1053/j.gastro.2007.03.059 17498510 (Pubitemid 46693756)
3. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Vincent HK, Innes KE, Vincent KR, Diabetes Obes Metab 2007 9 813 839 10.1111/j.1463-1326.2007.00692.x 17924865 (Pubitemid 47555204)
4. Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? Styskal J, Remmen HV, Richardson A, Salmon AB, Free Radical Biol Med 2012 52 46 58 10.1016/j.freeradbiomed.2011.10. 441
5. Nutrient-induced inflammation in the intestine. Ji Y, Sakata Y, Tso P, Curr Opin Clin Nutr 2011 14 315 321 10.1097/MCO.0b013e3283476e74
6. Role of intestinal inflammation as an early event in obesity and insulin resistance. Ding S, Lund PK, Curr OpinClin Nutr 2011 14 328 333 10.1097/MCO.0b013e3283478727
7. The capacity of food stuffs to induce innate immune activation of human monocytes in vitro is dependent on food content of stimulants of Toll-like receptors 2 and 4. Erridge C, Br J Nutr 2011 105 15 23 10.1017/S0007114510003004 20849668
8. Online Textbook of Bacteriology. Todar K, 2011 Bacterial Endotoxin. [textbookofbacteriology.net/endotoxin.html]
9. Intestinal alkaline phosphatase detoxifies lipopolysacchariDe and prevents inflammation in response to the gut microbiota. Bates JM, Akerlund J, Mittge E, Guillemin K, Cell Host Microbe 2009 2 371 382 (Pubitemid 350215326)
10. Accumulation of stimulants of Toll-like receptor (TLR)-2 and TLR4 in meat products stored at 5'C. Erridge C, J Food Sci 2011 76 72 79 10.1111/j.1750-3841.2010.02018.x 21535770
11. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Deopurkar R, Ghanim H, Friedman J, Abuaysheh S, Sia CL, Mohanty P, Viswanathan P, Chaudhuri A, Dandona P, Diabetes Care 2010 33 991 997 10.2337/dc09-1630 20067961
12. Increased Toll-like receptor activity in patients with metabolic syndrome. Jialal I, Huet BA, Kaur H, Chien A, Devaraj S, Diabetes Care 2012 35 900 904 10.2337/dc11-2375 22357188
13. Chylomicrons promote intestinal absorption of lipopolysaccharides. Ghoshal S, Witta J, Zhong J, De Williers W, Eckhardt E, J Lipid Res 2009 50 90 97 18815435
14. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, Forsblom C, Porsti I, Rissanen A, Kaprio J, Mustonen J, Groop PH, Lehto M, Diabetes Care 2011 34 1809 1815 10.2337/dc10-2197 21636801
15. Adopocyte-macrophage interaction may mediate LPS-induced low-graDe inflammation: potential link with metabolic complications. Nakarai H, Yamashita A, Nagayasu S, Iwashita M, Kumamoto S, Ohyama H, Hata M, Soga Y, Kushiyama A, Asano T, Abiko Y, Nishimura F, Innate Immun 2011 18 164 170 21239459
16. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Sun L, Yu Z, Ye X, Zou S, Li H, Yu D, Wu H, Chen Y, Dore J, Clement K, Hu FB, Lin X, Diabetes Care 2010 33 1925 1932 10.2337/dc10-0340 20530747
17. Inflammation, stress, and diabetes. Wellen KE, Hotamisligil GS, J Clin Invest 2005 115 1111 1119 15864338 (Pubitemid 40629025)
18. High glucose induced Toll-like receptor expression in human monocytes. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I, Diabetes 2008 57 3090 3098 10.2337/db08-0564 18650365
19. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. Lee JY, Sohn KH, Rhee SH, Hwang D, J Biol Chem 2001 276 16683 16689 10.1074/jbc. M011695200 11278967
20. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. Wong SW, Kwon MJ, Choi AMK, Kim HP, Nakahara K, Hwang DH, J Biol Chem 2009 284 27384 27392 10.1074/jbc.M109.044065 19648648
21. Macronutrient intake induces oxidative and inflammatory stress: potential releVance to atherosclerosis and insulin resistence. Dandona P, Ghanim H, Chaudhuri A, Dhindsa S, Kim SS, Exp Mol Med 2010 42 245 253 10.3858/emm.2010.42. 4.033 20200475
22. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Nijhuis J, Rensen SS, Slaats Y, Van Dielen FMH, Buurman WA, Greve JWM, Obesity 2009 17 2014 2018 10.1038/oby.2009.113 19390527
23. Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Kelley DS, Adkins Y, P Nutr Soc 2012 28 1 10
24. Prevention of insulin resistance by n-3 polyunsaturarted fatty acids. Fedor D, Kelley DS, Curr Opin Clin Nutr 2009 12 138 146 10.1097/MCO. 0b013e3283218299
25. Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. Kalupahana NS, Claycombe KJ, Newman SJ, Stewart T, Siriwardhana N, Mathhan N, Lichtenstein AH, Moustaid-Moussa N, J Nutr 2010 140 1915 1922 10.3945/jn.110.125732 20861209
26. n-3 Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N, Adv Nutr 2011 2 304 316 10.3945/an.111.000505 22332072
27. Structural analysis of the nontoxic lipid A of Rhodobacter capsulatus 37b4. Frauss JH, Seydel U, Weckesser J, Mayer H, Eur J Biochem 1989 180 519 526 10.1111/j.1432-1033.1989.tb14677.x 2714269 (Pubitemid 19111115)
28. Diphosphoryl lipid A obtained from the nontoxic lipopolysacchariDe of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Qureshi N, Takayama K, Kurtz R, Infect Immun 1991 59 441 444 1987057
29. The role of dairy products in supplying conjugated linoleic acid to mans diet: a review. Lawson RE, Moss AR, Givens DI, Nutr Res Rev 2001 14 153 172 10.1079/095442201108729178 19087420 (Pubitemid 32574407)
30. Conjugated linoleic acid production from linoleic acid by lactic acid bacteria. Kishino S, Ogawa J, Omura Y, Matsumura K, Shimuzu S, JAOCS 2002 79 159 163 10.1007/s11746-002-0451-4 (Pubitemid 34254937)
31. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Belury MA, Annu Rev Nutr 2002 22 505 531 10.1146/annurev.nutr.22.021302.121842 12055356 (Pubitemid 35221471)
32. Antiobesity mechanisms of action of conjugated linoleic acid. Kennedy A, Martinez K, Schmidt S, Mandrup S, Lapoint K, McIntosh MK, J Nutr Biochem 2010 21 171 179 10.1016/j.jnutbio.2009.08.003 19954947
33. Conjugated linoleic acid modulation of risk factors associated with atherosclerosis. Nakamura YK, Omaye ST, Nutr Metab 2008 5 22 10.1186/1743-7075-5-22
34. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Bassaganya-Riera J, Hontecillas R, Curr Opin Clin Nutr 2010 13 569 573 10.1097/MCO.0b013e32833b648e
35. Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth. Bougnoux P, Hajiaji N, Maheo K, Couet C, Chevalier S, Prog Lipid Res 2010 49 76 86 10.1016/j.plipres.2009.08.003 19715726
36. Conjugated linoleic acid isomers' roles in the regulation of PPAR and NF-BDNA binding and subsequent expression of antioxidant enzymes in human umbilical vein endothelial cells. Nakamura YK, Omaye ST, Nutrition 2009 25 800 811 10.1016/j.nut.2009.01.003 19299109
37. Modulation of oxidative stress by gamma-glutamylcysteine (GGC) and conjugated linoleic acid (CLA) in human umbilical vein endothelial cells. Nakamura YK, Dubick MA, Omaye ST, Food Chem Tox 2012 50 1854 1859 10.1016/j.fct.2012.03.066
38. Lipophilic compound-mediated gene expression and implication for intervention in reactive oxygen species (ROS)-related diseases: mini-review. Nakamura YK, Omaye ST, Nutrients 2010 2 725 736 10.3390/nu2070725 22254050
39. A meta-analysis of the effects of conjugated linoleic acid on fat-free mass in humans. Schoeller DA, Watras AC, Whigham LD, Appl Physiol Nutr Me 2009 34 975 978 10.1139/H09-080
40. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Whigham LD, Watras AC, Schoeller DA, Am J Clin Nutr 2007 85 1203 1211 17490954 (Pubitemid 46740460)
41. Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Dandona P, Ghanim H, Bandyopadhyay A, Korzeniewski K, Ling Sia C, Chaudhuri A, Diabetes Care 2010 33 2416 2423 10.2337/dc10-0929 20699433
42. Insulin as an anti-inflammatory and antiatherogenic modulator. Dandona P, Chaudhuri A, Ghanim H, Mohanty P, J Am Coll Cardiol 2009 53 14 S20 10.1016/j.jacc.2008.10.038 19179212
43. Free fatty acids in the presence of hugh glucose amplify monocyte inflammation via Toll-like receptors. Dasu MR, Jialal I, Am J Physiol- Endoc 2011 300 145 154
44. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Abel ED, Peroni O, Kim JK, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB, Nature 2001 409 729 733 10.1038/35055575 11217863 (Pubitemid 32144519)
45. Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements. Armoni M, Harel C, Bar-Yoseph F, Milo S, Karnieli E, J Biol Chem 2005 280 34786 34795 10.1074/jbc.M502740200 16096283 (Pubitemid 41504612)
46. Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology. Karnieli E, Armoni M, Am J Physiol-Endoc 2008 295 38 E45
47. Insulin resistance and increased lipolysis in bone marrow derived adipocytes stimulated with agonists of Toll like receptors. Franchini M, Monnais E, Seboek D, Radimerski T, Zini E, Kaufmann K, Lutz T, Reusch C, Ackermann M, Muller B, Linscheid P, Horm Metab Res 2010 42 703 709 10.1055/s-0030-1261872 20603780
48. Adaptive Immunity to Infection, in Immunobiology. Janeway CAJr, Travers P, Walport M, Shlomchik MJ, Immunobiology: the immune system in health and disease. 6th edition Garland Science, New York, Bachmann M, Casadevall A, Doherty P, Hengartner H, McGhee J, Potter M, 2005 409 459
49. Human gut microbes associated with obesity. Ley RE, Turnbaugh PJ, Klein S, Gordon JI, Nature 2006 444 1022 1023 10.1038/4441022a 17183309 (Pubitemid 46018512)
50. Molecular analysis of commensal host-microbial relationships in the intestine. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI, Science 2001 291 881 884 10.1126/science.291.5505.881 11157169 (Pubitemid 32120760)
51. Gut microbiota and its possible relationship with obesity. DiBaise JK, Zhang H, Crowell MD, Karajmalnik-Brown R, Decker GA, Rittmann BE, Mayo Clin Proc 2008 83 460 469 10.4065/83.4.460 18380992 (Pubitemid 351536471)
52. High fat diet determines the composition of the murine gut microbiome independently of obesity. Hildebrandt MA, Hoffmann C, Shrerrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD, Gastroenterology 2009 137 Hoffmann C 1716 1724 19706296
53. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the developmet of type 1 diabetes? Brugman S, Klatter FA, Visser JTJ, Wildeboer-Veloo ACM, Harmsen HJM, Rozing J, Bos NA, Diabetologia 2006 49 2105 2108 10.1007/s00125-006-0334-0 16816951 (Pubitemid 44168478)
54. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. De La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE, Am J Physiol Gastr 2010 299 440 448
55. Human nutrition, the gut microbiome and the immune system. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI, Nature 2011 474 327 336 10.1038/nature10213 21677749
56. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Backhed F, Manchester JK, Semenkovich CF, Gordon JI, PNAS 2007 104 979 984 10.1073/pnas.0605374104 17210919 (Pubitemid 46154722)
57. Changes in gut microbiota control metabolic enfotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R, Diabetes 2008 57 1470 1481 10.2337/db07-1403 18305141
58. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, Chen KT, Moss AK, Ramasamy S, Faruqui A, Hodin S, Malo PS, Ebrahimi F, Biswas B, Narisawa S, Millan JL, Warren HS, Kaplan JS, Kitts CL, Hohmann EL, Hodin RA, Gut 2010 59 1476 1484 10.1136/gut.2010.211706 20947883
59. Gut microbiota in health and disease. Sekirov I, Russell SL, Antunes CM, Finlay BB, Physiol Rev 2010 90 859 904 10.1152/physrev.00045.2009 20664075
60. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Raurtonen N, Sansonetti PJ, Burcelin R, EMBO Mol Med 2011 3 559 572 10.1002/emmm.201100159 21735552
61. Probiotics in man and animals. Fuller R, J Appl Bacteriol 1989 66 365 378 10.1111/j.1365-2672.1989.tb05105.x 2666378
62. Prebiotic effects: metabolic and health benefits. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Leotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A, Br J Nutr 2010 104 1 S63 20955646
63. Probiotics and immune health. Yan F, Polk DB, Curr Opin Gastroen 2011 27 496 501 10.1097/MOG.0b013e32834baa4d
64. Probiotics and prebiotics in infant nutrition. Parracho H, McCartney AL, Gibson GR, Proc Nutr Soc 2007 66 405 411 10.1017/S0029665107005678 17637093 (Pubitemid 47076238)
65. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection agaist atopic disease in the infant. Rautava S, Kalliomaki M, Isolauri E, J Allergy Clin Immun 2002 109 119 121 10.1067/mai.2002.120273 11799376 (Pubitemid 34112140)
66. Evidence of probiotics in prevention of allergy and asthma. Bjorksten B, Curr Drug Targets. Inflam Allergy 2005 4 599 604 10.2174/156801005774322135 (Pubitemid 41448366)
67. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Delzenne NM, Neyrinck AM, Backhed F, Cani PD, Nature Rev Endocrinol 2011 7 639 646 10.1038/nrendo.2011.126
68. Response of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Everard A, Lazarevis V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, Francois P, De Vos WM, Delzenne NM, Schrenzel J, Cani PD, Diabetes 2011 60 2775 2786 10.2337/db11-0227 21933985
69. Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroides and Frimicutes in lean and obese JCR:LA-cp rats. Parnell JA, Reimer RA, Br J Nutr 2011 18 1 13
70. The gut microbiome as therapeutic target. Cani PD, Delzenne NM, Pharm Therapuet 2011 130 202 212 10.1016/j.pharmthera.2011.01.012
71. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH, Biochim Biophys Acta 2006 1761 736 744 10.1016/j.bbalip.2006.05.007 16807088 (Pubitemid 44108749)
72. Prebiotic effects: metabolic and health benefits. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Leotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A, Br J Nutr 2007 104 1 S63
73. Bifidobacteria and Lactobacilli exhibited different mitogenic activity on murine splenocytes. He F, Morita H, Ouwehand AC, Int J Prob Preb 2006 1 77 82
74. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. Roller M, Rechkemmer G, Waltzl B, J Nutr 2004 134 153 156 14704309 (Pubitemid 38057439)
75. Permanent colonization by Lactobacillus casei is hindered by the low rate of cell devision in mouse gut. Lee YK, Ho PS, Low CS, Arvilommi H, Salminen S, Appl Environ Microb 2004 70 670 674 10.1128/AEM.70.2.670-674.2004 (Pubitemid 38568186)
76. Probiotics: determinants of survival and growth in the gut. Bezkorovainy A, Am J Clin Nutr 1998 73 399S 405S
77. The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: a randomized, placebo-controlled study. Roessler A, Forssten SD, Glei M, Ouwehand AC, Jahreis G, Clin Nutr 2011 31 22 29 21963389
78. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. Roesch LF, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, Li N, Mai V, Wasserfall CH, Schatz D, Atkinson MA, Neu J, Triplett EW, ISME J 2009 3 536 548 10.1038/ismej.2009.5 19225551
79. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Million M, Maraninchi M, Henry M, Armougom F, Richet H, Carrieri P, Valero R, Raccah D, Vialettes B, Raoult D, Int J Obes in press
80. Lactobacillus species shift in distal esophagus of high-fat-diet-fed rats. Zhao X, Liu XW, Xie N, Wang XH, Cui Y, Yang JW, Chen LL, Lu FG, World J Gastroentero 2011 17 3151 3157
81. Anticholesteremic property of Lactobacillus acidophilus yogurt fed to mature boars. Danielson AD, Peo ERJ, Shahani KM, Lewis AJ, Whalen PJ, Amer MA, J Anim Sci 1989 67 966 974 2497098
82. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. Tien MS, Girardin SE, Regnault B, Bourhis LL, Dillies MA, Coppee JY, Bourdet-Sicard R, Sansonetti PJ, Pedron T, Immun 2006 176 1228 1237 (Pubitemid 43099727)
83. Probiotics may reduce inflammation by enhancing peroxisome proliferator activated receptor gamma activation in HT-29 cells. Eun CS, Han DS, Lee SH, Jeon YC, Sohn JH, Kim YS, Lee J, Korean J Gastroentero 2007 49 139 146
84. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. Ewaschuk JB, Walker JW, Diaz H, Madsen KL, J Nutr 2006 136 1483 1487 16702308 (Pubitemid 43765349)
85. Inflammation and insulin resistance induced by trans-10, cis-12 conjugated linoleic acid depend on intracellular calcium levels in primary cultures of human adipocytes. Kennedy A, Martinez K, Chung S, LaPoint K, Hopkins R, Schmidt SF, Andersen K, Mandrup S, McIntosh MK, J Lipid Res 2010 51 1906 1917 10.1194/jlr.M005447 20154361
86. Trans-10, cis-12 conjugated linoleic acid instigates inflammation in human adpocytes compared to preadipocytes. Martinez K, Kennedy A, West T, Milatovic D, Aschner M, McIntosh MK, J Biol Chem 2010 285 17701 17712 10.1074/jbc.M109.043976 20353947
87. Differential effects of conjugated linoleic acid isomers in insulin-resistant female C57BI/6J mice. HalaDe GV, Rahman A, Fernandes G, J Nutr Biochem 2010 21 332 337 10.1016/j.jnutbio.2009.01.006 19423318
88. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR to suppress colitis. Bassaganya-Riera J, Viladomiu M, Pedradosa M, De Simone C, Carbo A, Shaykhutdinov R, Jobin C, Arthur JC, Corl BA, Vogel H, Storr M, Hontecillas R, PLoS ONE 2012 7 31238 10.1371/journal.pone. 0031238 22363592
89. Bacterial exopolysaccharides-a perception. Kumar AS, Mody K, Jha B, J Basic Microb 2007 47 103 117 10.1002/jobm.200610203 (Pubitemid 46953809)
90. Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. Ruas-Madiedo P, GueimonDe M, Margolles A, DlR-G CG, Salminen S, J Food Protect 2006 69 2011 2015 (Pubitemid 44384484)
91. Exopolysaccharides produced by Lactobacillus and Bifidobacterium strains abrogate in vitro the cytotoxic effect of bacterial toxins on eukaryotic cells. Ruas-Madiedo P, Medrano M, Salazar N, DLR-G CG, Perez PF, Abraham AG, J Appl Microb 2010 109 2079 2086 10.1111/j.1365-2672.2010.04839.x
92. Production, purification and structural characterization of an exopolysacchariDe produced by a probiotic Lactobacillus plantarum MTCC9510. Ismail B, Nampoothiri KM, Arch Microbiol 2010 192 1049 1057 10.1007/s00203-010- 0636-y 20957348
93. ExopolysacchariDe activities from probiotic bifidobacterium: Immunomodulatory effects (on J774A.1 macrophages) and antimicrobial properties. Wu MH, Pan TM, Wu YJ, Chang SJ, Chang MS, Hu CY, Int J Food Microbiol 2010 144 104 110 10.1016/j.ijfoodmicro.2010.09.003 20884069
94. Effects of the oral administration of the exopolysacchariDe produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Vinderola G, Perdigon G, Duarte J, Farnworth E, Matar C, Cytokine 2006 36 254 260 10.1016/j.cyto.2007.01.003 17363262 (Pubitemid 46529477)
95. Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms Tremella fuciformisand Phellinus baumii in ob/ob mice. Cho EJ, Hwang HJ, Kim SW, Oh JY, Baek YM, Choi JW, Bae SH, Yun JW, Appl Microbiol Biot 2007 75 1257 1265 10.1007/s00253-007-0972-2 (Pubitemid 46976685)
96. Kitada M:Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet. Uchida M, Ishii I, Inoue C, Watanabe AY, K, Hosoyama S, Toida T, Ariyoshi N, J Atherosclerosis Thromb 2010 17 980 988 10.5551/jat.4812
97. Immunomodulatory and antioxidantpotential of Lactobacillus exopolysaccharides. Liu CF, Tseng KC, Chiang SS, Lee BH, Hsu WH, Pan TM, J Sci Food Agr 2011 91 2284 2291
98. Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Delzenne NM, Neyrinck AM, Cani PD, MicrobCell Fact 2011 10 10 10.1186/1475-2859-10-S1-S10